These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31228100)

  • 1. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.
    Michaud K; Pope JE; Emery P; Zhu B; Gaich CL; DeLozier AM; Zhang X; Dickson CL; Smolen JS
    Rheumatol Ther; 2019 Sep; 6(3):409-419. PubMed ID: 31228100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF; Greenwald M; Bradley JD; Alam J; Arora V; Kartman CE
    Rheumatol Ther; 2018 Jun; 5(1):43-55. PubMed ID: 29680881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials.
    Fautrel B; Wu J; Wang D; Haladyj E; van de Laar MAFJ; Takeuchi T
    J Clin Rheumatol; 2023 Apr; 29(3):139-144. PubMed ID: 36473106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
    Emery P; Blanco R; Maldonado Cocco J; Chen YC; Gaich CL; DeLozier AM; de Bono S; Liu J; Rooney T; Chang CH; Dougados M
    RMD Open; 2017; 3(1):e000410. PubMed ID: 28405473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib
    Yang Y; Xu J; Xu J; Li X; Hu J; Li X; Zhang X; He D; Bao C; Li Z; Wang G; Zerbini CAF; Spindler AJ; Kannowski CL; Wu H; Ji F; Zhan L; Liu M; Li Z
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006964. PubMed ID: 33959198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
    Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
    Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.
    Fautrel B; Kirkham B; Pope JE; Takeuchi T; Gaich C; Quebe A; Zhu B; de la Torre I; De Leonardis F; Taylor PC
    J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31492040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial.
    Taylor PC; Lee YC; Fleischmann R; Takeuchi T; Perkins EL; Fautrel B; Zhu B; Quebe AK; Gaich CL; Zhang X; Dickson CL; Schlichting DE; Patel H; Durand F; Emery P
    J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31212775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
    Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
    Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib.
    Pope JE; Lee YC; Curtis JR; Mo D; Xie L; Dickson CL; Schlichting DE; Cardoso A; Simon LS; Taylor PC
    ACR Open Rheumatol; 2022 Mar; 4(3):254-258. PubMed ID: 34913611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
    Schlueter M; Finn E; Díaz S; Dilla T; Inciarte-Mundo J; Fakhouri W
    Clinicoecon Outcomes Res; 2019; 11():395-403. PubMed ID: 31239736
    [No Abstract]   [Full Text] [Related]  

  • 18. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Emery P; Tanaka Y; Cardillo T; Schlichting D; Rooney T; Beattie S; Helt C; Smolen JS
    Arthritis Res Ther; 2020 May; 22(1):115. PubMed ID: 32414425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids.
    van Vollenhoven R; Helt C; Arora V; Zhong J; Correia AP; de la Torre I; Muram D
    Rheumatol Ther; 2018 Dec; 5(2):525-536. PubMed ID: 30357613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.